Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gen

StreetInsider04-23

WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429906010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-23 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429906010","market":"us","top_or_hot":-1,"title":"Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gen","media":"StreetInsider","content":"<div>\n<p>WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics (\"Affinia\"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23097186\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 04:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23097186><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics (\"Affinia\"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23097186\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=23097186","article_id":"2429906010","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429906010","pubTimestamp":1713817920,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics , an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus  vectors and gene therapies for rare and prevalent devastating diseases, today announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system  such as amyotrophic lateral sclerosis , as well as the Company's high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy  2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4117":"多元化保险","BK4121":"生命科学工具和服务","LENZ":"Therapeutics","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK4097":"系统软件","BK4588":"碎股","AFG":"美国金融集团有限公司","BK4107":"财产与意外伤害保险","CNS":"科恩-斯蒂尔斯金融","BK4139":"生物科技","GENE":"基因技术ADR","BK4135":"资产管理与托管银行","GEN":"GEN DIGITAL INC"},"translate_title":"Affinia Therapeutics在美国Gen学会上介绍了关于新型促心肌病和血脑屏障渗透AAV衣壳以及遗传性心肌病和散发性ALS的临床前疗效和安全性的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFG":1,"CNS":1,"GEN":1,"GENE":1,"LENZ":1},"content_text":"WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics (\"Affinia\"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system (CNS) such as amyotrophic lateral sclerosis (ALS), as well as the Company's high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.\n\n\n\n\n\nAffinia has leveraged its proprietary platform to rationally design capsids with increased tropism to cardiac muscle, skeletal muscle, or CNS with more uniform tissue distribution than AAV9. This improved biodistribution is attained while detargeting the liver and dorsal root ganglia (DRG), both potential sites of toxicity. Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity. Preclinical efficacy and safety results with a cardiotropic vector encoding for the BAG3 protein provide proof of concept for the treatment of multiple genetic cardiomyopathies and with a blood-brain barrier (BBB)-penetrant vector encoding for the knockdown of Ataxin-2 (Atxn2), a gene believed to be involved in sporadic ALS, provide proof of concept for the treatment of multiple CNS diseases including ALS, supporting the development of potential medicines across a spectrum of rare and prevalent diseases.\n\"We are excited to unveil data on our next-generation bespoke capsids that demonstrate robust cardiac transduction while detargeting the liver and DRG. Similarly, our BBB-penetrant capsid detargets the liver and DRG and shows a promising profile for treating multiple CNS diseases,\" said Rick Modi, Affinia's Chief Executive Officer. \"Our initial preclinical results in genetic cardiomyopathies and sporadic ALS are in line with our purpose to bring life-changing gene therapies to people suffering from life-threatening and disabling diseases.\"\nOne oral presentation showcases data from Affinia's novel, BBB-penetrant AAV capsid with a potential therapeutic application to sporadic ALS. The data show that the capsid delivers an Atxn2 microRNA cargo that adequately decreases Atxn2 mRNA in non-human primates. Another oral presentation features Affinia's proprietary manufacturing process in HEK-293 suspension cells, yielding greater than 50% full capsids with greater than 1e15vg/L at harvest, with broad applicability across conventional and novel AAV capsids and with significant potential cost advantages relative to other gene therapies.Affinia will also hold two poster presentations. The first poster showcases data that confirm the novel cardiotropic AAV capsid's safety and therapeutic efficacy in an animal model of cardiac dysfunction with a potential therapeutic application in genetic cardiomyopathies. The company will also present a poster on a screening platform for the discovery of novel, next-generation CNS tropic capsids, based on binding to cell receptors that facilitate BBB transcytosis and with potential applicability to non-AAV targeted delivery modalities.The oral and poster presentation details are provided below. Abstracts can be found at https://annualmeeting.asgct.org/. Data from the oral presentations are embargoed until 6:00 am ET on the presentation day.\nOral presentations\nTitle: Reduction of Atxn2, a therapeutic target for sporadic ALS, in non-human primates using a novel, intravenously delivered AAV capsidPresenter: Giridhar Murlidharan, Ph.D., Senior Director, Head of Vector Translational Biology, AffiniaSession: Neurologic Diseases IVDate/Time: Friday, May 10, 2024, 4:00-4:15 pm ETLocation: Room 307-308Abstract Number: 304\nTitle: A proprietary HEK293 AAV production system can achieve greater than 50% full capsids with greater than 1e15vg/L at harvest enabling scalable chromatography-based polishing with high yield and purity Presenter: Matt Edwards, MBA, Senior Director, Head of Process Science, AffiniaSession: AAV Manufacturing IIIDate/Time: Friday, May 10, 2024, 4:00-4:15 pm ETLocation: Ballroom 3Abstract Number: 290\nPoster presentations\nTitle: Systemic Administration of a Novel Cardiotropic AAV Vector Encoding BAG3 Rescues Left Ventricle Functional Deficits in a Mouse Model of Myocardial InfarctionPresenter: Lisa Stanek, Ph.D., Vice President, Translational Science, AffiniaDate/Time: Wednesday, May 8, 2024, 12:00-7:00 pm ETLocation: Exhibit HallAbstract Number: 605\nTitle: Identification of Novel CNS-Tropic AAVs Using In Vitro Binding to Candidate Receptors Combined With In Vivo Screening, Generative AI, and Structural ModelingPresenter: Charles Albright, Ph.D., Chief Scientific Officer, AffiniaDate/Time: Thursday, May 9, 2024, 12:00-7:00 pm ETLocation: Exhibit HallAbstract Number: 982\nIn addition, Affinia has been invited to present on the rational design of cardiotropic capsids that detarget the liver and DRG. Sherry Cao, Ph.D., Senior Vice President, Computational Science will deliver the presentation entitled, \"Machine-learning guided rational design of cardiotropic capsids that detarget liver and DRG,\" on Saturday, May 11, 2024 at 8:00 am ET in Room 339-342.\nThe Company also announced members from its leadership team have been invited to chair the following sessions:\nScientific Symposium: \"Innovations in Cardiac Gene and Cell Therapy\"Chair: Laura Richman, MBA, D.V.M., Ph.D., DACVP, Chief Development OfficerDate/Time: Saturday, May 11, 2024, 8:00-9:45 am ETLocation: Room 339-342\nCategory of Abstracts: B5 – Neurologic Diseases Section 4Chair: Lisa Stanek, Ph.D., Vice President, Translational ScienceDate/Time: Friday, May 10, 2024, 3:45-5:00 pm ETLocation: Room 307-308\nAbout Affinia TherapeuticsAffinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' proprietary Affinia Rationally designed Therapeutics (ART) platform is intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com.\n View original content to download multimedia:https://www.prnewswire.com/news-releases/affinia-therapeutics-to-present-data-on-novel-cardiotropic-and-bbb-penetrant-aav-capsids-and-preclinical-efficacy-and-safety-in-genetic-cardiomyopathies-and-sporadic-als-at-the-american-society-of-gene--cell-therapy-2024-annual-m-302121290.html\nSOURCE Affinia Therapeutics","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429906010"}